Atopic Dermatitis

The AJMC® Atopic Dermatitis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin condition that typically develops in early childhood.

Latest News

Lebrikizumab improved quality of life and mental health in patients with atopic dermatitis in a pair of studies. | Image Credit: InfiniteStudio - stock.adobe.com
Lebrikizumab Improves Quality of Life, Disease Control in Patients With Atopic Dermatitis

May 15th 2025

Two studies explored the quality-of-life impacts of lebrikizumab for atopic dermatitis, finding its benefits extend beyond physical symptom improvements.

FDA stamp of approval | Image Credit: Olivier Le Moal - stock.adobe.com
FDA Approves Tapinarof Cream 1% for Patients With Atopic Dermatitis

December 16th 2024

man resting hands on top of walking cane | Image Credit: sergign - stock.adobe.com
Study Finds Increased Impaired Mobility by Sex, Age in Atopic Dermatitis

June 30th 2024

E-cigarettes | Image Credit: lezinav - stock.adobe.com
Parental e-Cigarette Use May Increase Pediatric AD Risk

May 22nd 2024

Female patient with AD | Image Credit: Prostock-studio - stock.adobe.com
Study: Visible AD Impacts Romantic Relationships, Occupation, Sexual Health of French Female Patients

May 19th 2024

Topical Therapies for the Treatment of Atopic Dermatitis: Balancing Safety, Efficacy, and Access

Develop a deeper understanding of the atopic dermatitis (AD) patient journey, explore topical therapies and treatment sequencing advancements, and gain insight regarding the payer’s perspective on AD therapies.

Atopic Dermatitis Payer Perspectives

More News

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo